One of the unanticipated blocks to conducting a trial at MD Anderson was the trial requirement that cohorts had not previously been treated for OM. By the time patients arrived at MD Anderson many were disqualified for this reason.
There was the added caveat of intense competition for cancer drug trial cohorts.
CTIX adapted by choosing more initial treatment sites where there was less chance of these disqualifying treatments having been administered.
News 
Market Data 
Discover 
AI
